



BB Adamant Global Medtech und Services AA Class

Factsheet as of 31 October 2015

> Performance in %

Since	1m	YTD	1yr	3yrs	5yrs	Incept.
Fund net	5.8	4.7	13.9	67.2	63.4	68.1
Benchmark	6.7	6.8	15.3	52.6	52.9	57.5
Annualised			3yrs	5yrs	Incept.	
Fund net			18.7	10.3	7.0	
Benchmark			15.1	8.9	6.1	

> Fund Description


The BB Adamant Global Medtech und Services fund invests globally in the most interesting medtech companies and healthcare service providers. This segment currently includes more than 500 stock market-listed companies worldwide. The medtech companies alone generate USD 350 billion in revenues each year at a growth rate of over 5%. The service providers also cover a broad spectrum of the entire value-creation chain, with the strongest growth from companies active in healthcare IT or niche players. These firms increase efficiency and effectiveness in the healthcare sector and ultimately supplement the value-creation chain of medtech companies in the more complex healthcare environment. Bellevue has longstanding experience in primary research with medtech companies and service providers and regularly visits the companies on site.

> Fund Facts

Swiss Sec. No.		3'433'473
ISIN		CH0034334737
Fund Inception Date		03.03.2008
Fund Currency		CHF
Net Asset Value	CHF	1'680.61
Shares Outstanding	in thousands	21.82
Subfund Size Class	million	36.67
Total Fund Size	million	101.24
Last Dividend Pay.	CHF	n.a.
52-Week High	CHF	1'841.45
52-Week Low	CHF	1'385.53
TER p.a.		1.83%
Fund Manager	Bellevue Asset Management AG, Zürich	
Custodian Bank	Zürcher Kantonalbank	
Fund Manag. Company	Swisscanto Fondsleitung AG, Zürich	
Benchmark	3-Monats-LIBOR CHF until 31.10.2013	
Benchmark	MSCI World Health Care Equipment and Services Index	

TER p.a. refers to latest published annual- or semi-annual report.

> Indexed Performance



Since fund inception or at the longest for the last five years

> Investment Strategy

The demographic ageing process, major technological advances in the field of medicine and lifestyle changes are among the driving factors for growth in the medtech sector. The fund aims to combine the innovative strengths of the established medtech companies from the industrialised countries in the area of medical devices and products with the economic efficiencies of emerging markets companies in terms of cost structure and development of easier to use devices for the Asian markets.


> Main Investment Principles

The fund's strategic focus targets an equally weighted diversification for the longer-term between North America, Europe and Asia. The main emphasis on a stock selection level is on highly innovative mid cap companies and on larger global companies with solid balance sheet structures and attractive product pipelines in growing sub-sectors or countries.


> 10 Largest Positions

Unitedhealth Group	12.61%
Medtronic	7.20%
Abbott	7.11%
Express Scripts	6.73%
Cigna Corporation	6.26%
Aetna	5.92%
Humana	5.22%
McKesson	4.53%
Anthem	4.06%
Stryker	3.26%
Total Exposure	117.3%

> Breakdown by Sector



> Breakdown by Country



> Key Figures

	1 year annualised realised	3 years annualised realised	5 years annualised realised
Volatility Fund	21.0%	14.5%	13.3%
Sharpe Ratio	0.6	1.2	0.7

The fund has been approved in Switzerland by the supervisory authority, the Swiss Financial Market Authority (FINMA).

Disclaimer

This Publication is for information purposes only and does not explicitly target any person who by domicile or nationality is prohibited to receive such information according to applicable law. Investors are advised that past performance is not an indicator of current or future performance and that the performance data do not take account of commission and expenses charged on the issue and redemption of units. The BB Adamant Funds are investment funds under Swiss law in the "Other funds for traditional investments" category and have been established under the Swiss Collective Investment Schemes Act. The Fund's prospectus respectively key investor information, regulations and annual report may be obtained free of charge from the Fund Manager and the Custodian Bank. This document was produced by Zürcher Kantonalbank ("ZKB") applying highest diligence standards in good faith. ZKB does not warrant any guarantee with regard to correctness and completeness and waives any claim for losses that may occur through the use of this information. This Publication is neither an offer nor a recommendation for the purchase or sale of financial products or financial services and does not discharge the recipient from his own judgement. Particularly, ZKB recommends that the recipient, if need be by consulting professional guidance, assess the information in consideration of his personal situation with regard to legal, regulatory and tax consequences that might be invoked. The present document is not the result of the department "financial analysis" as defined in the rules of the "Directives on the Independence of Financial Research" edited by the Swiss Bankers Association, hence these rules do not apply to this document.

This document is for distribution and / or redistribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons.

The enclosed document is only made available on the condition that it will be exclusively used by the recipient and must not be forwarded to other persons or reproduced either in part or in full. The units will not be placed as part of an active offer. The intended distribution of the units was therefore not reported to the financial market supervisory authority and the units are not part of a published prospectus in Austria. All enclosed information relating to the units thus neither represents part of a prospectus within the meaning of the Investment Fund Act (InvFG), information within the meaning of § 21 of the Alternative Investment Fund Managers Act (AIFMG) nor a prospectus within the meaning of the Capital Markets Act (KMG).

If Balfidior Fondsleitung AG, Adamant Funds or Zürcher Kantonalbank enter into a business or contractual relationship with a client whose registered office, permanent or temporary residence, domicile, administrative office or management is in Austria, these contractual terms and conditions arise exclusively at the client's own initiative and discretion. Investors are hereby informed that earnings, capital gains and capital gains tax on units are not currently reported by a tax representative to the Swiss Federal Ministry of Finance (BMF) nor to the Austrian OeKB. Accordingly, there may be detrimental taxation consequences. Taxation depends on the personal circumstances of the investor and may change in future.

This publication and the information contained in it must not be distributed and / or redistributed to, used or relied upon by, any person (whether individual or entity) who may be a US person under Regulation S under the US Securities Act of 1933. US persons include any US resident; any corporation, company, partnership or other entity organized under the any law of the United States; and other categories set out in Regulation S.

This document does not constitute an offer to sell or a solicitation or invitation to subscribe for or to make an offer to buy any securities, nor does it provide a basis for any contract or obligation of any kind. This document is not a prospectus within the meaning of article 652a or 1156 the Swiss Code of Obligations or Article 27 of the listing rules of SIX Swiss Exchange AG.

Copyright © 2015 Zürcher Kantonalbank. All rights reserved.